Dow Up, bioAffinity Technologies Up

All three major indices rose today.

The NASDAQ gained 119.96 points.

The DOW gained 137.81 points.

The S&P gained 27.45 points.

Technology stocks helped lift the broader market, contributing to the Nasdaq's advance as investors continued to rotate into select growth names despite ongoing concerns about oil prices and the war with Iran. Airline and travel stocks also supported sentiment after stronger revenue outlooks from major carriers helped ease some worries about the near-term economic backdrop.

The broader market also participated in the advance, with gains across multiple sectors including energy, financials, and consumer discretionary companies. The rise in the S&P 500 suggested that buying activity was not limited to a single segment of the market.

Analysts noted that the coordinated gains across the major indices indicate improving investor confidence, even as markets continue to weigh higher oil prices, geopolitical developments, and expectations surrounding monetary policy ahead of the Federal Reserve's latest decision.

Investors will continue watching upcoming economic reports and corporate developments later this week for further signals about the economy and financial markets' directions.

All this as bioAffinity Technologies rose 0.83 points to end the day at $2.72 per share. The biotechnology company drew strong investor attention as traders reacted to continued momentum around its CyPath Lung diagnostic platform and recent company updates highlighting commercial and clinical progress.

The company recently reported record 2025 revenue and unit sales for CyPath Lung, with revenue from the test increasing 87% year over year, test volume rising 99%, and the number of ordering physician sites increasing 67%. Investors also focused on a new case-study update highlighting CyPath Lung's role in noninvasive lung cancer diagnostics.

Together, the company's recent diagnostic data and strong commercial growth in CyPath Lung helped drive significant buying interest in bioAffinity Technologies shares during today's trading session.